Skip to main content
Clinical Trials/CTRI/2022/01/039577
CTRI/2022/01/039577
Completed
Phase 4

CLINICAL EVALUATION OF EFFICACY AND LONGEVITY OF NANOSEAL AND ADMIRA PROTECT DESENSITIZING AGENTS ON REDUCING DENTINE HYPERSENSITIVITY AFTER SINGLE DOSE APPLICATION.A RANDOMIZED, SPLIT MOUTH CLINICAL TRIAL.

ESWARI PRIYA GUMMADI0 sites55 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: K030- Excessive attrition of teeth
Sponsor
ESWARI PRIYA GUMMADI
Enrollment
55
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
January 23, 2023
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
ESWARI PRIYA GUMMADI

Eligibility Criteria

Inclusion Criteria

  • Patients with age ranged from 18\-50 years, with the presence of at least 1 sensitive molar each, in at least two quadrants, with a Schiff cold air sensitivity score of \>\=2 on occlusal surfaces of attrited molars, that are not going to be planned to receive any restorations are going to be included in the study.

Exclusion Criteria

  • Patients who are already using desensitizing agents, teeth with Abrasions, Erosions, Cracked enamel, Carious lesions, Defective restorations, Pathology of pulp.
  • Patients with active Periodontal disease and patients using medication with analgesic drugs.
  • Pregnant or lactating women, and patients with eating disorders and regurgitation or chronic diseases are going to be excluded from the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials